BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 22449646)

  • 1. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
    McMakin DL; Olino TM; Porta G; Dietz LJ; Emslie G; Clarke G; Wagner KD; Asarnow JR; Ryan ND; Birmaher B; Shamseddeen W; Mayes T; Kennard B; Spirito A; Keller M; Lynch FL; Dickerson JF; Brent DA
    J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):404-11. PubMed ID: 22449646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Joy returns last: anhedonia and treatment resistance in depressed adolescents.
    Rubin DH
    J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):353-5. PubMed ID: 22449641
    [No Abstract]   [Full Text] [Related]  

  • 3. Saving lives: can we predict and prevent adolescent suicide?
    Weder N
    J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):339-40. PubMed ID: 22449635
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    Brent D; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller M; Vitiello B; Ritz L; Iyengar S; Abebe K; Birmaher B; Ryan N; Kennard B; Hughes C; DeBar L; McCracken J; Strober M; Suddath R; Spirito A; Leonard H; Melhem N; Porta G; Onorato M; Zelazny J
    JAMA; 2008 Feb; 299(8):901-913. PubMed ID: 18314433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
    Vitiello B; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes TL; DeBar L; Lynch F; Dickerson J; Strober M; Suddath R; McCracken JT; Spirito A; Onorato M; Zelazny J; Porta G; Iyengar S; Brent DA
    J Clin Psychiatry; 2011 Mar; 72(3):388-96. PubMed ID: 21208583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
    Asarnow JR; Emslie G; Clarke G; Wagner KD; Spirito A; Vitiello B; Iyengar S; Shamseddeen W; Ritz L; Birmaher B; Ryan N; Kennard B; Mayes T; DeBar L; McCracken J; Strober M; Suddath R; Leonard H; Porta G; Keller M; Brent D
    J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):330-339. PubMed ID: 19182688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial.
    Woldu H; Porta G; Goldstein T; Sakolsky D; Perel J; Emslie G; Mayes T; Clarke G; Ryan ND; Birmaher B; Wagner KD; Asarnow JR; Keller MB; Brent D
    J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):490-8. PubMed ID: 21515198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy.
    Wagner KD; Asarnow JR; Vitiello B; Clarke G; Keller M; Emslie GJ; Ryan N; Porta G; Iyengar S; Ritz L; Zelanzny J; Onorato M; Brent D
    J Child Adolesc Psychopharmacol; 2012 Feb; 22(1):5-10. PubMed ID: 22251022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.
    Lynch FL; Dickerson JF; Clarke G; Vitiello B; Porta G; Wagner KD; Emslie G; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes T; DeBar L; McCracken JT; Strober M; Suddath RL; Spirito A; Onorato M; Zelazny J; Iyengar S; Brent D
    Arch Gen Psychiatry; 2011 Mar; 68(3):253-62. PubMed ID: 21383263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Brent DA
    Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.
    Emslie GJ; Mayes T; Porta G; Vitiello B; Clarke G; Wagner KD; Asarnow JR; Spirito A; Birmaher B; Ryan N; Kennard B; DeBar L; McCracken J; Strober M; Onorato M; Zelazny J; Keller M; Iyengar S; Brent D
    Am J Psychiatry; 2010 Jul; 167(7):782-91. PubMed ID: 20478877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
    Hilton RC; Rengasamy M; Mansoor B; He J; Mayes T; Emslie GJ; Porta G; Clarke GN; Wagner KD; Birmaher B; Keller MB; Ryan N; Shamseddeen W; Asarnow JR; Brent DA
    J Am Acad Child Adolesc Psychiatry; 2013 May; 52(5):482-92. PubMed ID: 23622849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors.
    Sáiz-Ruiz J; Ibáñez A; Díaz-Marsá M; Arias F; Padín J; Martín-Carrasco M; Montes JM; Ferrando L; Carrasco JL; Martín-Ballesteros E; Jordá L; Chamorro L
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1129-34. PubMed ID: 12452535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance use and the treatment of resistant depression in adolescents.
    Goldstein BI; Shamseddeen W; Spirito A; Emslie G; Clarke G; Wagner KD; Asarnow JR; Vitiello B; Ryan N; Birmaher B; Mayes T; Onorato M; Zelazny J; Brent DA
    J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1182-92. PubMed ID: 19858762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.
    Martinotti G; Sepede G; Gambi F; Di Iorio G; De Berardis D; Di Nicola M; Onofrj M; Janiri L; Di Giannantonio M
    J Clin Psychopharmacol; 2012 Aug; 32(4):487-91. PubMed ID: 22722509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
    Whyte EM; Basinski J; Farhi P; Dew MA; Begley A; Mulsant BH; Reynolds CF
    J Clin Psychiatry; 2004 Dec; 65(12):1634-41. PubMed ID: 15641868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.